Find recruiting clinical trials for kidney cancer (RCC) in the UK — from surgical approaches to immunotherapy-TKI combinations. See where trials fit into your treatment pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your treatment journey
Partial or radical nephrectomy for localised disease, sometimes with surveillance or adjuvant therapy
Standard: Partial nephrectomy (kidney-sparing) or radical nephrectomy; active surveillance for small renal masses
Tyrosine kinase inhibitors target tumour blood vessel formation
Standard: Pazopanib, sunitinib, or cabozantinib as first-line for patients where immunotherapy isn't suitable
Combination immunotherapy has become the standard first-line approach for most advanced RCC
Standard: Pembrolizumab + axitinib, nivolumab + cabozantinib, or ipilimumab + nivolumab (poor risk)
After first-line progression, trials test sequential therapies and new mechanisms
Emerging: Belzutifan (HIF-2α inhibitor), lenvatinib + pembrolizumab, novel bispecific antibodies, and CAR-T approaches
Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for about 13,300 new cases per year in the UK. Clear cell RCC (ccRCC) makes up about 75% of cases. Risk factors include smoking, obesity, and family history. Many are found incidentally on imaging.
RCC has been a success story for immunotherapy — from early cytokine treatments to modern IO+TKI combinations, survival has improved significantly. But many patients still progress. Trials are testing next-generation approaches including HIF-2α inhibitors and personalised immunotherapy.
Treatment choices depend on your IMDC (International Metastatic RCC Database Consortium) risk score — based on blood tests, performance status, and time from diagnosis to treatment. Your oncologist uses this to determine whether you're favourable, intermediate, or poor risk, which guides therapy selection.
Loading trials from ClinicalTrials.gov...